This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis Index (PCI) ≤10
Treatment-naïve patients who have not received chemotherapy, radiotherapy, or any other antitumor therapy prior to the start of the clinical trial;
Age between 18 and 75 years;
Male or non-pregnant, non-lactating female;
Gastric or gastroesophageal junction adenocarcinoma confirmed by gastroscopy and pathological diagnosis;
Inability to comply with the study protocol or procedures;
Known HER2-positive status;
Known diagnosis of squamous cell carcinoma, undifferentiated carcinoma, or other histological types of gastric cancer, or adenocarcinoma mixed with other histological types;
Current conditions or diseases affecting drug absorption;